- Home
- ARWR vs LIVN Comparison
ARWR vs LIVN Comparison
Compare ARWR & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARWR
- LIVN
- Stock Information
- Founded
- ARWR 2003
- LIVN 1987
- Country
- ARWR United States
- LIVN United Kingdom
- Employees
- ARWR N/A
- LIVN N/A
- Industry
- ARWR Biotechnology: Pharmaceutical Preparations
- LIVN Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- ARWR Health Care
- LIVN Health Care
- Exchange
- ARWR Nasdaq
- LIVN Nasdaq
- Market Cap
- ARWR 2.6B
- LIVN 2.6B
- IPO Year
- ARWR 1993
- LIVN 1993
- Fundamental
- Price
- ARWR $19.90
- LIVN $47.44
- Analyst Decision
- ARWR Buy
- LIVN Buy
- Analyst Count
- ARWR 11
- LIVN 7
- Target Price
- ARWR $43.33
- LIVN $67.14
- AVG Volume (30 Days)
- ARWR 2.5M
- LIVN 447.2K
- Earning Date
- ARWR 02-10-2025
- LIVN 02-25-2025
- Dividend Yield
- ARWR N/A
- LIVN N/A
- EPS Growth
- ARWR N/A
- LIVN 759.09
- EPS
- ARWR N/A
- LIVN 0.43
- Revenue
- ARWR $2,500,000.00
- LIVN $1,241,739,000.00
- Revenue This Year
- ARWR $3,336.78
- LIVN $10.18
- Revenue Next Year
- ARWR $124.29
- LIVN $5.43
- P/E Ratio
- ARWR N/A
- LIVN $110.76
- Revenue Growth
- ARWR N/A
- LIVN 11.04
- 52 Week Low
- ARWR $17.05
- LIVN $43.15
- 52 Week High
- ARWR $36.72
- LIVN $64.48
- Technical
- Relative Strength Index (RSI)
- ARWR 49.40
- LIVN 44.11
- Support Level
- ARWR $17.57
- LIVN $46.75
- Resistance Level
- ARWR $21.84
- LIVN $49.96
- Average True Range (ATR)
- ARWR 1.06
- LIVN 1.24
- MACD
- ARWR 0.11
- LIVN -0.09
- Stochastic Oscillator
- ARWR 54.57
- LIVN 21.50
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.
About LIVN LivaNova PLC
UK-based LivaNova was born of a combination between Cyberonics in the us and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management and heart valve businesses. It derives roughly half of its revenue from the us market, another 21% from Europe, and the remainder from the rest of the world.